Astellas has acquired Xyphos Biosciences, Inc., gaining Xyphos’ novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform, as well as immuno-oncology talent, to develop and advance new ways to target and control immune cells to find, modulate and destroy targeted cells throughout the body.   “At Astellas, immuno-oncology is a Primary Focus of our research and development strategy, and we are working on the development of next-generation ...